AdipoGen Life Sciences COVID-19 antiviral research compounds

Wednesday, 27 May, 2020 | Supplied by: Sapphire Bioscience


There are no approved drugs to treat the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that causes coronavirus disease 2019 (COVID-19). Existing drugs, which have a known favourable safety profile, are being examined for strategies to treat the disease and fast-track a treatment plan. Several influenza and HIV drugs are currently undergoing clinical trial in coronavirus patients. The rational selection of drugs already on the market is being made based on their ability to inhibit any proteins essential for virus-receptor interaction and/or viral life cycle.

AdipoGen Life Sciences’ range of Small Molecule SARS-CoV-2 Inhibitors and Modulators offers potential tools for in vitro studies of COVID-19. The company’s product range includes research compounds targeting viral transcription, replication and maturation.

Online: www.sapphirebioscience.com
Phone: 02 9698 2022
Related Products

Bio-Rad Laboratories anti-idiotypic antibodies and Human IgM-FcSpyCatcher reagent

Bio-Rad Laboratories has extended its range of recombinant monoclonal anti-idiotypic antibodies...

ProSci Incorporated apoptosis antibodies

ProSci Incorporated provides an extensive catalogue of apoptotic antibodies including death...

TdB Labs polysaccharides

TdB Labs' polysaccharide portfolio consists of both fluorescent and non-fluorescent...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd